Research Use Only: This product is supplied for laboratory research and in-vitro studies. Not for human or veterinary administration.
Semax 30mg
- ACTH(4-10) Analogue: Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, developed 1982 Russian Academy, ACTH(4-7) + Pro-Gly-Pro extension for metabolic stability, 800+ publications, no hormonal activity
- Multi-Modal Neuroprotection: BDNF upregulation (1.4× protein, 3× mRNA hippocampus), monoamine modulation (180% 5-HIAA), copper chelation (K_D 1.3×10⁻¹⁵ M), anti-amyloid activity, transcriptomic ischemia protection
- Clinical Status: Russian FDA approved, List of Vital & Essential Drugs 2011, Phase I-II trials 1990-1996, extensive clinical use for stroke/cognitive disorders/optic neuropathy, low toxicity profile
- Mechanistic pathway studies
- In vitro receptor profiling
- HPLC verified identity and purity
Ships same-day if ordered before 2PM EST
Research Overview
Semax (ACTH(4–7)-PGP; also referenced as Pro-Gly-Pro-ACTH in registry records) is a synthetic heptapeptide derived from a defined segment of adrenocorticotropic hormone (ACTH). In the scientific literature, Semax has been used as a research tool in neurobiology and molecular signaling studies, including investigations of activity-dependent gene programs, neurotrophin-linked transcriptional responses, monoaminergic pathway markers, and systems-level network activity measured with experimental imaging and omics approaches.
Preclinical publications describe Semax-associated changes in transcriptional signatures across CNS-relevant tissues and report modulation of neurotrophin-related gene expression (including BDNF and NGF) in controlled animal and cell-based experimental designs.
This product is intended exclusively for in vitro laboratory research by qualified professionals. Not for human consumption. Not approved by the FDA.
Published Research Briefs
Our research team has published evidence-checked briefs covering the science behind this compound. Each brief reviews primary sources and grades claims independently.